United Therapeutics (UTHR) Cash & Current Investments (2009 - 2026)

United Therapeutics has disclosed Cash & Current Investments across 18 years of filings, most recently posting $2.7 billion for Q2 2026.

• In Q2 2026, Cash & Current Investments fell 12.67% year-over-year to $2.7 billion; the TTM figure through Jun 2026 stood at $2.7 billion (down 12.67% YoY), while the FY2025 annual figure was $2.9 billion, down 10.61% from the prior year.
• Cash & Current Investments came in at $2.7 billion for Q2 2026 at United Therapeutics, up from $2.2 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $3.3 billion in Q3 2024 to a low of $2.2 billion in Q1 2026.
• Average Cash & Current Investments over 5 years is $2.8 billion, with a median of $2.9 billion recorded in 2022.
• Year-over-year, Cash & Current Investments jumped 47.03% in 2022 and plunged 35.15% in 2026.
• Over 5 years, Cash & Current Investments stood at $2.8 billion in 2022, then increased by 5.47% to $3.0 billion in 2023, then climbed by 9.11% to $3.3 billion in 2024, then retreated by 10.61% to $2.9 billion in 2025, then decreased by 8.83% to $2.7 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $2.7 billion in Q2 2026, $2.2 billion in Q1 2026, and $2.9 billion in Q4 2025.